Objective: Observational studies have suggested that arterial distensibility decreases during menopause; however, its relationship with hormone therapy use remains controversial. We prospectively studied distensibility and hormone therapy use at different menopause stages.
A rterial distensibility has emerged as a useful prognostic indicator of cardiovascular disease (CVD) beyond standard risk factors such as hypertension, hyperlipidemia, and diabetes. 1 Distensibility is a measure of an artery's ability to expand in response to changes in pulse pressure and is an inverse measure of arterial stiffness. Loss of distensibility has been associated with the development of CVD, hypertension, and stroke in healthy individuals. [2] [3] [4] In addition, markers of arterial distensibility, such as pulse pressure, have helped clarify the results of trials showing different clinical outcomes with differing antihypertensive therapy regimens despite similar reductions in blood pressure. 5 With aging, CVD risk factors shift unfavorably for women and coincide temporally with a decline in estrogen levels and with menopause. Cross-sectional data examining the influence of the menopausal transition on arterial distensibility have primarily shown an acceleration of age-related increase in stiffness [6] [7] [8] [9] ; however, cross-sectional data have not tested independent relationships between distensibility and age versus menopausal hormonal changes. 10, 11 In addition, the impact of hormone therapy (HT) on arterial distensibility remains controversial; some observational studies have suggested benefits whereas other studies have not found HT to have substantive impact. [12] [13] [14] Randomized controlled trials measuring distensibility in postmenopausal women using HT have not shown benefits to date potentially because of the late initiation of HT (after vascular changes have already occurred). 15, 16 The present study prospectively examines relationships between menopause stage and changes in carotid artery distensibility across a 3-year period. It also examines the relationship between initiation of HT and distensibility. In addition, we sought to determine the relationship between arterial distensibility, hormonal change, and CVD risk factors. We hypothesized that arterial distensibility would decline across time and that estrogen levels would decrease concomitantly, with the greatest decline occurring during the menopausal transition. Furthermore, we hypothesized that HT, through estrogen therapy, would be beneficially associated with these changes.
METHODS

Study population
The Los Angeles Atherosclerosis Study is a communitybased cohort study of employees of a major utility company in southern California. All study participants were recruited from the same company from four different job categories: union, management, administrative, and other. Exclusion criteria were applied only at baseline and included a selfreported history of CVD (angina, myocardial infarction, revascularization, or stroke) and current treatment of cancer. Participants aged 40 to 60 years were randomly sampled from all employees within the strata of sex, age, ethnicity, and smoking status. Hispanics and smokers were oversampled. The participation rate at study entry was 85% for a total cohort of 573 participants, of which 280 were female. The population for the present analysis comprised 161 women aged 45 to 60 years at study entry who had sufficient information to determine menopause status and distensibility index (DI) at baseline and 3-year follow-up. Baseline examination was conducted between 1995 and 1996, and follow-up was conducted 3 years later (mean [SD], 3.0 [0.24] y). At baseline visit and 3-year visit, women underwent evaluation of carotid intima-media thickness (cIMT). The study protocol was approved by the institutional review committees at Cedars-Sinai Medical Center and University of Southern California. All women provided a written informed consent form.
Determination of menopause status
We used the menopause status algorithm developed by the Women's Ischemia Syndrome Evaluation study to determine menopause stage at each study visit. This algorithm, which uses a combination of self-reported reproductive history and menstrual cycle pattern and dates with serum reproductive hormone levels, has been published elsewhere. 17 Reproductive hormone levels were assessed by the Los Angeles Atherosclerosis Study reproductive hormone core laboratory using validated steroid and protein assay methods for total estradiol, bioavailable estradiol, estrone, progesterone, follicle-stimulating hormone (FSH), and luteinizing hormone. [18] [19] [20] In addition to using the menopause status algorithm, the Los Angeles Atherosclerosis Study Hormone Committee, led by reproductive endocrinologists and scientists (S.B., G.B., and F.S.), reviewed and adjudicated menopause stage at baseline and 3 years based on all reproductive and relevant biometric information. Menopause stage at baseline was categorized as premenopausal (Pre), perimenopausal (Peri), and postmenopausal (Post). At 3-year visit, study participants were categorized as remaining premenopausal, remaining postmenopausal, or transitioning (Tran)-defined as a change from premenopausal to perimenopausal, from premenopausal to postmenopausal, from perimenopausal to perimenopausal, or from perimenopausal to postmenopausal.
Measurement of risk factors
Study participants completed a nurse-administered questionnaire at each visit to determine demographic variables. A study nurse performed physical examinations and obtained height and weight measurements, with participants in light clothing. Blood pressure (seated) was determined using a standard sphygmomanometer, with two separate readings after a minimal 10-minute rest. Serum and plasma samples were obtained after an overnight fast of at least 8 hours. HT use and name of hormone preparation were also attained at baseline visit and follow-up visit.
Distensibility index
DI was calculated using the following formula 21 :
2=diastolic diameter of CCA ð Þ Â diastolic diameter of CCA ½ ð Àsystolic diameter of CCA=pulse pressureÞ Diastolic internal diameter of common carotid artery (CCA) and systolic internal diameter of CCA were measured as part of previously published cIMT protocol. 22 Although ARTERIAL DISTENSIBILITY AND HORMONE THERAPY cIMT was measured at each of the four visits, the systolic internal diameter and diastolic internal diameter needed to calculate DI were only measured at baseline visit and at 3-year follow-up visit.
Statistical methods
Continuous variables are summarized as mean (SD), and dichotomous variables are reported as percentage. Highly skewed variables are reported as median (interquartile range). Change in variable across time (D) was obtained by subtracting baseline values from values obtained at 3-year follow-up, such that a positive value indicates an increase in the variable across time and a negative value indicates a decrease. Differences across menopause stages (Tables 1-3) were assessed by analysis of variance or nonparametric Kruskal-Wallis test, where appropriate.
We used generalized linear modeling, with menopause status groups entered as a class variable. Differences in mean baseline DI and mean change in DI among menopause status groups ( Fig. 1 ) used the CONTRASTS option. Before multivariate modeling, the distribution of all potential predictors was evaluated for deviations from normality and for clinically implausible outliers. Variables highly skewed to the right were log-transformed, and those skewed to the left underwent power transformation. DI was normally distributed and had no major outliers. For the final predictive model, all possible clinical and laboratory parameters in Table 1 (except age) were first added (one at a time in separate models) to the menopause stages to assess whether they were independent predictors of DI change and/or whether they affected the relationship in question. Variables with P < 0.20 or variables whose introduction in the model changed the relationship between menopause stages and DI change were entered into forward stepwise regression. Other possible covariates were individually added until the final model contained only significant covariates. With the SOLUTION option in PROC GLM, the final model displays the P values across all menopause groups and the parameters of each menopause stage compared with the reference group, in addition to independent covariates. Only three potential predictors had missing values (glucose, low-density lipoprotein, and FSH), none of which entered the models. All tests were two-sided, and P 0.05 was considered statistically significant. All analyses were performed with SAS software version 9.3 (SAS Institute).
RESULTS
Women's mean (SD) age was 51.5 (4.6) years; 85 women (53%) were white, and 45 women (28%) were Hispanic. Most Baseline characteristics for study participants are shown in Table 1 . As expected, there was a statistically significant difference in FSH and age between Pre, Tran, and Post women (P < 0.0001). In addition, use of antihypertensive medications and serum triglyceride levels were different, with use of antihypertensive medications and triglyceride levels being higher in the Tran/HT group (P ¼ 0.047 and P ¼ 0.037, respectively). There were no significant differences in the remaining variables across menopause stages.
Baseline hemodynamic variables across menopause stages are shown in Table 2 . Mean baseline systolic blood pressure (SBP) was significantly different and was lowest in Tran/No HT women (P ¼ 0.024). Similarly, pulse pressure varied among all groups (P ¼ 0.033). Among the variables used to calculate baseline DI, the internal diameter of CCA measured during diastole was relatively larger in Post women (P ¼ 0.037). Baseline DI was significantly different by menopause stage, with higher baseline DI in Pre and Tran/No HT women compared with Tran/HT and Post women (P < 0.0001).
Changes in hemodynamic variables across a 3-year period (D), by menopause stage, are shown in Table 3 . With the exception of DFSH and DDI (P < 0.0001 and P ¼ 0.046, respectively), there were no statistical differences in other variables. Baseline DI and DDI, by menopause stage, are illustrated in Figure 1 . The difference in DDI between Post women taking HT and Post women not taking HT was not statistically significant (P ¼ 0.38); therefore, both subgroups were combined to form the reference group. We further evaluated changes in risk factors across time as potential covariates. Adjusting for each covariate separately, we found that two significant (P < 0.0001) covariates (change in SBP and change in pulse pressure) enhanced the statistical relationship between menopause stage and DI (P ¼ 0.019 and P ¼ 0.0003, respectively). There was a strong correlation (baseline, r ¼ À0.71; follow-up, r ¼ À0.63) between DI and pulse pressure. The only other significant covariate-change in heart rate-did not substantially modify the relationship between menopause stage and DI. Table 4 presents the final multivariate model (with postmenopause as menopause stage reference) and independent covariates. The model R 2 was 0.55. Among covariates, only change in heart rate (P ¼ 0.003) and change in pulse pressure (P < 0.0001) remained independent predictors of change in DI. In comparison with the reference group (Post women), Pre and Tran/No HT women had a significantly faster decline in DI (P ¼ 0.002 and P ¼ 0.001, respectively). In contrast, although Tran/HT women experienced a somewhat faster decline in DI compared with Post women, this difference was not statistically significant (P ¼ 0.21).
Because of strong collinearity with menopause stage, age was not included in the final model. Adding baseline body mass index (P ¼ 0.51) or change in body mass index (P ¼ 0.16)-a potential confounder-to the model did not alter the significant relationship between decline in DI and menopause status or the other covariates.
DISCUSSION
Our prospective study demonstrates that DI significantly differs by menopause stage. At baseline, DI was higher in Pre and Tran/No HT women and was lower in Tran/HT and Post women. Across a 3-year period, the largest decline in DI occurred in the Tran/No HT group, whereas the lowest decline in DI was found in the Tran/HT group compared with the Post group. These findings suggest that HT use during transition (before postmenopause) is beneficially associated with decline in arterial distensibility. Furthermore, postmenopausal HT seems to have no beneficial relationship with distensibility. Finally, our results suggest that higher SBP and higher pulse pressure modify menopause status and decline in DI.
Our findings are consistent with those of a previous study of 93 premenopausal age-matched women and 93 postmenopausal women not using HT. 8 A significantly lower arterial distensibility was observed in postmenopausal women, further suggesting that, after controlling for age, estrogen status plays an important role in vascular function. In addition, a lower distensibility correlated with the number of years that a woman was postmenopausal, suggesting that distensibility is negatively associated with cumulative years of estrogen loss. Prior studies have also shown that menopause may augment age-related increase in arterial stiffness. 9, 23 Staessen et al 23 evaluated distensibility and pulse-wave velocity in 315 women (matched with 315 men) as they transitioned through menopause across 5.2 years. They found that arterial distensibility declined with age and that-after controlling for age, cardiovascular variables, and hormone use-Post women had greater pulse-wave velocity than Pre women. In addition, these results could not be reproduced in age-matched male controls, suggesting that menopause and estrogen loss may contribute to arterial stiffness above the effects of age. Similarly, our study found that the greatest decline in arterial distensibility occurred in Pre and Tran women not taking HT and that this difference was statistically significant compared with Post women.
Unlike most published studies examining arterial function and women taking HT, our study is unique in that it further differentiates by menopause stages to assess the relationship between distensibility and HT use. Our results indicate that because there was a slower decline in DI among Tran women taking HT compared with Post women, HT use during the menopausal transition may potentially slow the observed changes in arterial function. Prior studies have shown evidence that vascular changes may begin in the earliest stages of menopause and that the menopausal transition accelerates age-related decline in endothelial function and stiffness. 24, 25 A number of studies have also shown that arterial distensibility declines more rapidly in women than in men beginning around age 45 years, coinciding with the stage of early menopausal transition where estrogen fluctuations may begin. 26, 27 The change in distensibility is not related to sex differences such as arterial size or baseline compliance. 22 This greater reduction in distensibility may contribute to higher CVD risk and increased prevalence of systolic hypertension in older women. 28 Observational studies investigating the impact of HT on vascular function in postmenopausal women have yielded mixed results, with some showing improvement in arterial elasticity 12, 13, [29] [30] [31] [32] and others indicating no benefit. 14, 21 Kawecka-Jaszcz et al 12 examined 76 postmenopausal women and found that there was significant improvement in pulsewave velocity (a surrogate for arterial compliance) after 3 months of HT. Although not as robust, a retrospective study of 56 postmenopausal women also found that HT improved 
SHUFELT ET AL
pulse-wave velocity as early as 4 weeks. 31 Interestingly, one study showed that withdrawal of HT in 11 postmenopausal women resulted in significantly worse arterial compliance after 1 month. 13 To date, however, randomized controlled trials have failed to demonstrate that HT in postmenopausal women results in vascular improvement. 21, 33 In addition, recent results from the Kronos Early Estrogen Prevention Study did not find a difference in cIMT between HT (both transdermal and oral) and placebo among postmenopausal women on early menopause. 34 These data support our finding that HT use in Post women was not related to a significant change in decline in DI compared with nonuse of HT. Although we did not observe a difference in change in DI when we directly compared Tran women on and Tran women off HT, our findings are consistent with a prior randomized trial of Tran women that found no difference in arterial distensibility or compliance at 6 and 24 months after HT use compared with placebo. 16 It is possible that differences in arterial function between women on HT and women off HT may not be readily apparent in Tran women because estrogen levels are still fluctuating. Other studies have shown that structural arterial changes, such as cIMT and adventitial diameter, may worsen as early as 3 months after the final menstrual cycle. 24, 35 Furthermore, although the effects of progesterone on vascular reactivity are not entirely clear, evidence suggests that progesterone may counteract some of the vasodilatory effects of estrogen. 36, 37 Therefore, use of combination estrogen-progesterone HT in 34% of Tran women in our study may have attenuated estrogen-mediated changes in distensibility that would otherwise have been identified in the transition period. Finally, it is possible that the spectrum of women included as part of the Tran group (including premenopausal to perimenopausal and premenopausal to postmenopausal) was too broad to capture a significant change in vascular function across the 3-year study period.
In addition to aging, the decline in arterial distensibility during the menopausal transition may be related to lower serum estrogen levels. In addition to a direct atheroprotective effect, 38 estrogen has been shown to reduce endothelial dysfunction and to improve vascular reactivity across a short period. [39] [40] [41] At the biochemical level, estrogen enhances endothelium-dependent vasodilatation via reduced endothelin release, stimulation of nitric oxide levels, and increased production of nitric oxide synthase, prostacyclin, and endothelium-derived hyperpolarizing factor. 37 These estrogenmediated effects may mitigate the effects of low-grade inflammation, oxidative stress, and associated biomarkers of endothelial dysfunction that have been implicated in arterial stiffening. 42, 43 With respect to CVD risk factors, our study found that adding SBP and pulse pressure to our final model affected the relationship between menopause and decline in DI. Other studies have identified additional risk factors associated with reduced arterial distensibility, including obesity, 44 daily insulin intake, 45 smoking, 46 oxidized low-density lipoprotein, 42 African-American race, 47 increased high-density lipoprotein, 47 and HIV. 48 Although we assessed similar participant characteristics at baseline and on follow-up, statistical significance was not reached. One reason why our study may not have found these variables to be statistically significant is that we assessed change in covariates across time as opposed to absolute values at baseline or on follow-up.
Our results show that pulse pressure, which can serve as a marker of underlying arterial stiffness, increased across menopause stages. This has been demonstrated in a prior prospective study, which showed that younger age at onset of menopause was associated with higher pulse pressure, compared with older age at menopause. 49 Higher pulse pressure has also been shown to be an independent predictor of adverse cardiovascular events. 50 Post women with higher baseline pulse pressure have a more rapid progression of atherosclerosis. 51 With regard to blood pressure, prior studies have shown a significant association between higher blood pressure and carotid stiffness. 52, 53 Similar to pulse pressure, arterial stiffness is an independent predictor of increased coronary events in women with hypertension. 54 The increase in arterial stiffness may increase blood pressure by creating a high pulsewave velocity that augments pressure. 55 Advancing age in women is marked by predominance of sympathetic tone and decreased vagal tonic modulation of heart rate. 56 Furthermore, decrease in nitric oxide activity and diminished blood flow response to endothelium-dependent and endotheliumindependent stimuli are observed with aging. 57 There is evidence of hormonal involvement given the variation in radial artery distensibility observed during the menopause cycle. 58 The rapid decline in distensibility during the menopausal transition may potentiate the increased pulse pressure and SBP seen with aging or vice versa.
Potential study limitations
Given the observational nature of this study, our findings indicate only an association-not impact or causalitybetween arterial distensibility and changes in menopause and HT use. The transition through menopause is a gradual process that may not be accurately reflected by individual data points. However, the input of three reproductive endocrinologists, in conjunction with the menopause status algorithm, provides assurance about the classification of each study participant. In addition, the results of Table 2 provide construct validity demonstrating consistency with markers known to change during the menopausal transition. Although we took a comprehensive approach to assessing all hemodynamic variables and measures of DI, the results of the study could not be adjusted for unmeasured variables such as physical activity. Therefore, we cannot definitely exclude that aging and use of HT may be surrogates for other factors not included in the study. Another potential limitation is that use of HT in this study was not randomized and that the conclusion that HT may impact arterial distensibility should be interpreted with caution. The variability in the dose, type, and route of administration of HT could have led to differential effects on arterial distensibility. The generalizability of the results ARTERIAL DISTENSIBILITY AND HORMONE THERAPY may also be limited by the fact that the participants in this study had no known CVD; therefore, the effects of HT on arterial distensibility during the menopausal transition in the setting of significant atherosclerosis cannot be deduced. Finally, the small number of participants in the menopause groups may have underpowered the study and masked other significant findings, such as other covariates that may be independent predictors of change in DI or a significant difference in decline in DI comparing Tran and/or Post women on and off HT.
CONCLUSIONS
Compared with Post women, Pre and Tran women not using HT show the largest decline in arterial distensibility. These findings indicate that the menopausal transition is associated with reduced vascular compliance. HT seems to affect arterial distensibility only if taken during the transitional period of menopause, indicating that the perimenopausal window presents a critical time during which changes in arterial function may occur, increasing the risk of CVD. Additional prospective studies are needed to confirm these findings and to assess whether the impact of HT on arterial distensibility is sustained in the long term.
